392 trials
Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage III Pancreatic Cancer
Primary: Number of Participants With Adverse Events as Determined by CTCAE Version 4.03 — 1; 1; 4; 2 Participants
Heart Failure · Obesity · Type 2 Diabetes Mellitus
Primary: The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With…
Larynx · Lip · Oral Cavity
Primary: Cytokine/Chemokine Profile
Psoriasis
Primary: Measured MEMS Adherence- Number of Days With a Correct Number of Doses Taken — 15.14; 20.22 Days
Chronic Graft Versus Host Disease
Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373
Autism Disorder
Primary: M50 Latency (Left Hemisphere) — 90.9; 87.4; 89.3 ms
Alzheimer's Disease
Primary: Frequency of Adverse Events Over the Duration of the Study by Study Arm — 8; 1 Participants
Asthma
Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…
Cancer
Primary: HADS Anxiety — 15.14; 16.93 score on a scale
Stroke
Primary: Change in Compensatory Step Execution Time — -119.7; -4.2 msec
Adnexal Mass
Primary: Diagnostic Accuracy of Subharmonic Ultrasound Imaging Compared to Standard Ultrasound or Contrast Enhanced Magnetic Resonance Imaging (MRI) — 70; 56 percent accurate…
Aging
Primary: Percent Change in Type 2 Myofiber Cross Sectional Area — 18.5; 14.5 Percent change
Rosacea
Primary: Kallikrein 5 (KLK5) Protease Activity — 581.1; 816.5 RFU/uL
Methamphetamine Dependence
Primary: Effect of Entacapone on Methamphetamine-induced Mood — 12.500; 13.750; 7.500; 9.833 units on a scale
Breast Cancer
Primary: Change in Cognitive Function Scores With Intervention - HVLT and COWA — 49.04; 44.93; 42.28; 43.33 score